Skip to main content
. 2014 Sep 3;9(9):e106289. doi: 10.1371/journal.pone.0106289

Figure 5. LXR agonists block pancreatic cancer cell progression through the cell cycle.

Figure 5

A, GW3965 treatment arrests a significant proportion of the cells in the G1/G0 stage of the cell cycle as measured by propidium iodide staining and flow cytometry. B, Fewer cells are found in S, G2, or M phases following ligand treatment. C, BrdU-pulse analysis demonstrates that GW3965 treatments reduce transit through the S-phase of the cell cycle. D, E, F Representative cell cycle analysis diagram of BxPC-3, MIA-PaCa-2, and PANC-1 cells respectively. G, H, I Density plot depicting the number of cells staining for BrdU as a measure of S-phase transit in BxPC-3, MIA-PaCa-2, and PANC-1 cells. Asterisks indicated statistically significant changes.